Enliven therapeutics reports first quarter financial results and provides a business update

Announced positive proof of concept data from phase 1 clinical trial of elvn-001 in cml, achieving an initial cumulative mmr rate of 44% (7/16) by 12 weeks in response-evaluable patients
ELVN Ratings Summary
ELVN Quant Ranking